Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (9102)	5/18/2006 7:34:53 PM
From: Qualified Opinion	Read Replies (1) \| Respond to of 9523

Wyeth enters race for Pfizer's OTC business By Lina Saigol in London and James Politi in New York Published: May 18 2006 23:43 \| Last updated: May 18 2006 23:43 Wyeth, the US pharmaceuticals group, has joined the list of bidders vying to acquire Pfizer's consumer healthcare division in an auction that could value the maker of Sudafed and Listerine at more than $14bn. Wyeth is expected to make an offer for Pfizer's over-the-counter business ahead of the next deadline for bids on June 6, according to people familiar with the situation. Link: news.ft.com